Fig. 5: Alterations in liver fat content from baseline assessed by MRI-PDFF upon completion of the 28-day treatment. | Nature Communications

Fig. 5: Alterations in liver fat content from baseline assessed by MRI-PDFF upon completion of the 28-day treatment.

From: ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial

Fig. 5

a Columns representing LS means with blue error bars reflecting two-sided 95% CIs from an ANCOVA model, with absolute change from baseline as the dependent variable and the baseline values as a covariate; b Relative changes from baseline, columns representing means with blue error bars reflecting standard deviation (SD). Each gray dot represents an individual (each group, N = 9). Source data are provided as a Source Data file.

Back to article page